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Background: The contribution of occupational exposures to COPD and their interaction with cigarette smoking on
clinical pattern of COPD remain underappreciated. The aim of this study was to explore the contribution of
occupational exposures on clinical pattern of COPD.
Methods: Cross-sectional data from a multicenter tertiary care cohort of 591 smokers or ex-smokers with COPD
(median FEV1 49%) were analyzed. Self-reported exposure to vapor, dust, gas or fumes (VDGF) at any time during
the entire career was recorded.
Results: VDGF exposure was reported in 209 (35%) subjects aged 31 to 88 years. Several features were significantly
associated with VDGF exposure: age (median 68 versus 64 years, p< 0.001), male gender (90% vs 76%; p< 0.0001),
reported work-related respiratory disability (86% vs 7%, p< 0.001), current wheezing (71% vs 61%, p = 0.03) and hay
fever (15.5% vs 8.5%, p< 0.01). In contrast, current and cumulative smoking was less (p = 0.01) despite similar
severity of airflow obstruction.
Conclusion: In this patient series of COPD patients, subjects exposed to VDGF were older male patients who
reported more work-related respiratory disability, more asthma-like symptoms and atopy, suggesting that, even in
smokers or ex-smokers with COPD, occupational exposures are associated with distinct patients characteristics.
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Chronic obstructive pulmonary disease (COPD) is cur-
rently viewed as a consequence of interactions between
genetic and environmental factors. Tobacco smoking is
the most important risk factor for COPD [1], but other
environmental factors such as occupational exposures
are likely to contribute in some patients [2]. In 2010, the
American Thoracic Society estimated that more than
20% of COPD cases are attributable to occupational ex-
posure [3].
Most studies documenting the association between
COPD and occupational exposures have been performed
in workplace settings or in general population samples
and community-based cohorts. Only one patient series* Correspondence: dcaillaud@chu-clermontferrand.fr
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reproduction in any medium, provided the orspecifically assessed the characteristics of COPD patients
with a history of occupational exposures. Historically,
the identification of work-related COPD has been based
on the observation of an excess occurrence of COPD
among exposed workers in specific industries [4]. Subse-
quently, general population-based studies such as the
ECRHS [5] or community-based cohorts of patients with
COPD [6-8] found an increased risk of COPD in subjects
exposed to vapors, dust, gas, fumes (VDGF) or working
in agricultural, paper, cleaning, wood and food proces-
sing industries. In the only available series of COPD
patients (n = 185), VDGF exposure was associated with
sputum production and increased dyspnea [9]. In most
studies, occupational exposures were assessed using
questionnaires with broad terms encompassing multiple
exposures (VDGF), which appear reasonably effective in
identifying subjects significantly exposed to occupational
air pollutants [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of COPD, it might be hypothesized that occupational
exposures could be associated with specific phenotypic
traits such as atopy, since many occupational air pollu-
tants have sensitizing properties that could interact with
genetic predisposition [11]. However, this hypothesis has
not been adequately tested yet.
The present analysis was designed to explore the influ-
ence of occupational exposures on disease characteristics




The present study is based on the analysis of cross-
sectional data from a previously described cohort of COPD
patients recruited between January 2005 and August 2008
in 17 university respiratory medicine departments located
throughout France [12]. Respiratory physicians prospect-
ively recruited smokers or ex-smokers (>10 pack-years cu-
mulative tobacco consumption) in stable condition (no
history of exacerbation requiring medical treatment for the
previous 4 weeks) with a GOLD (Global Initiative on Ob-
structive Lung Disease)-based diagnosis of COPD (post-
bronchodilator FEV1/FVC ratio< 70%) [13]. Patients with
a main diagnosis of bronchiectasis, asthma or any signifi-
cant respiratory disease other than COPD were excluded.
The study was approved by the Ethics Committee of Ver-
sailles (France) and all patients provided informed written
consent.
Data collection
We used a standardized case report form that covered
demographic data, cumulative tobacco smoking, and
clinical and lung function characteristics in stable condi-
tion. Symptoms of chronic bronchitis and dyspnea were
evaluated using questions derived from the European
Community Respiratory Health Survey (ECRHS).
Current (during the previous year) history of sputum
production and wheezing was assessed [14]. Pulmonary
function tests were performed according to international
standards [15]. The number of self-reported acute
exacerbations of COPD was assessed and exacerbations
were classified as mild, moderate (use of antibiotics or oral
corticosteroids) or severe (hospitalization or emergency
department visit). Health related quality of life was evalu-
ated using the Saint George’s Respiratory Questionnaire
(SGRQ) [14].
Risk factors
Prior occupational exposures were assessed by the fol-
lowing ECRHS-derived question: “Have you ever worked
in a job which exposed you to vapors, dust, gas, or
fumes?” [5]. A history of transient work-relatedrespiratory disability was assessed by the question: “Have
you ever had to stop transiently your job because it
affected your breathing? “Permanent work-related re-
spiratory handicap was defined by a positive answer to
the question “Have you ever had to stop definitely your
job because it affected your breathing?”. Patients who
reported VDGF exposure were questioned on the job
position that they occupied during the longest period of
time. Answers were analyzed using a previously pub-
lished specific job exposure matrix (JEM) that provided a
semiquantitative estimate (none, low or high) of expos-
ure to three broad categories of agents: organic dust,
mineral dust, or gas/fumes [16,17].
Patients were categorized (i) as current smokers or ex-
smokers (smoking cessation at least 12 months ago) and
(ii) as smokers or ex-smokers of ≥ or < 20 pack-years [16].
Patients were considered as atopic when they reported
a history of hay fever.
Statistical analysis
Since some variables were not continuously distributed,
data are reported as median [Q1-Q3] for quantitative
variables. Percentages were used to describe categorical
variables. Univariate comparisons between patients
exposed or not to VDGF were performed using Chi-
square test for qualitative variables and the two-sided
non-parametric Wilcoxon test for quantitative variables.
A p value <0.05 was considered for statistical signifi-
cance. Analysis was performed with SAS software
(version 9.2).
Ethic statement
The research protocol was approved by the ethics com-
mittee of Versailles (France) and all patients provided
informed written consent.
Results
Analysis of demographic characteristics and risk factors in
COPD subjects according to VDGF exposure
Among the 615 COPD patients included in the cohort,
required data were available in 591 (96%). Exposure to
VDGF was reported by 209 subjects (35%) and was more
common among males than females (90% vs 10%,
Table 1). The median age was 65 years, patients report-
ing VDGF exposure being about 4 years older than
VDGF- subjects. Altogether, 27% of patients were still
current smokers at inclusion in the cohort. Cumulative
smoking was 41 (26–57) pack-years. Current and cumu-
lative smoking were also less in COPD patients with
VDGF exposure, despite similar severity of airflow ob-
struction (see following table). Cumulative smoking and
FEV1 (% predicted) were not correlated (r = 0.08). With
regard to atopy, hay fever was almost twice more fre-
quent in the VDGF+population. A trend towards a
Table 1 Characteristics of the study population (N= 591): data are median [Q1-Q3]
All n = 591 VDGF + n= 209 (35%) VDGF - n= 382 (65%) P
Male/female ratio (%) 80.7/19.3 89.9/9.1 75.6/24.4 <0.001 (a)
Age 65 [57–73] 68 [59–74] 64 [57–72] 0.0005 (b)
Smoking status Current/past (%) 27/73 22/78 29/71 0.04 (a)
Smoking, pack-yr 41 [26–58] 39 [20–54] 42 [28–60] 0.01 (b)
Hay fever 11 15.5 8.5 <0.01 (a)
Life-time atopic dermatitis 7 8 .8 6.1 NS (a)
Life-time asthma 11.3 14.7 9.5 0.0614 (a)
(a) = Chi-Square Test.
(b) =Wilcoxon rank-sum test.
p values are for differences between VGDF + and VGDF-.
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and GOLD stage did not differ between exposed and
non-exposed subjects. They were not influenced by the
level of cumulative smoking.
Among patients reporting VDGF exposure, job-exposure
matrix (JEM) analysis found that 61% were exposed to
mineral dusts, 34% to biological pollutants and 73% to gas,
vapors or fumes. Altogether, 3% of the whole patient popu-
lation were exposed to one category of pollutants, 20% to
two and 8% to three categories. Current smokers were less
represented among subjects exposed to mineral dusts
(17% vs 30% in the remaining population) and to vapors,
gas and fumes (20% vs 29%).
Symptoms and health status
In terms of symptoms, although chronic bronchitis was
not more frequent among VDGF+COPD patients
(overall prevalence: 73%), they reported current sputum
production more often. Similarly, current wheeze and
life-time wheeze were more frequent in patients with
VDGF exposure, which was associated with poorer
health status (Table 2).
Work disability
COPD patients with VDGF exposure reported signifi-
cantly more often an impact of their respiratory situation
on their ability to work: 28.5% of VDGF-exposed sub-
jects had to stop working definitely due to breathing dif-
ficulties vs 20.3% in non-exposed patients. In addition,
34.7% (vs 25.4%) had to stop working transiently because
they experienced respiratory problems. Altogether, only
36.8% of VDGF-exposed subjects (vs 54.3% of non-
exposed subjects) reported no impact of their breathing
situation on work.
Main differences between VDGF+ and VDGF- COPD
patients are summarized in Figure 1.
Discussion
In this patient series, the clinical characteristics of COPD
appeared to be modulated by occupational exposures:patients reporting exposure to vapors, dust, gas or fumes
at some point during their career also reported more fre-
quently a history of hay fever, current wheeze and transient
or permanent occupational disability. They were older and
predominantly men with less current and cumulative
smoking, despite similar severity of airflow obstruction.
This is the first patient series identifying such specific clin-
ical characteristics associated with occupational exposures
in smokers and ex-smokers with COPD.
Role of atopy in the development of COPD related to
occupational exposures
Since the late 1960s, it has been known that, although
cigarette smoking is a risk factor for COPD, only 20 to
30% of cigarette smokers develop airways disease, sug-
gesting that genetic susceptibility plays an important role
as a determinant of disease occurrence.
In our cohort, occupational exposures were associated
with atopy, despite the fact that all COPD patients were
smokers or ex-smokers. This observation suggests that
atopy and at least some occupational exposures interact
to favour the development of the disease. Some decades
ago, the Dutch hypothesis suggested that asthma and
COPD are different manifestations of a single disease en-
tity, called chronic nonspecific lung disease. It was sug-
gested that endogenous factors (e.g., sex and age),
environmental factors (e.g., allergens, occupation, and
smoking) and genetic factors (including those predispos-
ing to atopy and airway hyperresponsiveness) all play a
role in the pathogenesis of the disease [18,19].
Indeed, there is evidence that atopy, independently of its
association with bronchial hyperesponsiveness, may be
associated or have a role in the pathogenesis of COPD
[18,20]. In a general population study, COPD was asso-
ciated not only with smoking but also with occupational
exposures and hay fever [21]. Other studies found an in-
verse association between atopy, as defined by IgE level,
and the FEV1/FVC ratio, independently of smoking status
[22]. Some genes, such as those coding IL-13 and IL-17F,
might be involved in a global model of shared genetic
Table 2 Symptoms according to VDGF exposure
All n = 591 VDGF + N=209 VDGF – 382 P value
Chronic bronchitis (%) 73.3 75.3 72.2 NS (a)
Shortness of breath (MRC) 2 [1–2] 2 [1–2] 2 [1–2] NS (b)
Life-time wheeze (%) 65 71.9 61.1 0.0371 (a)
Exacerbations/patient/yr 1 [0–3] 1 [0–3] 1 [0–3] NS (b)
FEV1 (postBD, % predicted) 49 [35–66] 51.6 [37.2–67.1] 47.2 [33.7–65.3] 0.08 (b)
GOLD stages (%) 0.15 (a)
I 5.6 7.7 4.5
II 43 44.5 42.2
III 33.2 33.5 33
IV 18.3 14.4 20.4
Current sputum1 2 [1–4] 3 [1 – 4]. 2 [1 – 4]. 0.035 (b)
Current wheeze1* 1 [0–2] 2 [0 – 3]. 1 [0 – 2]. 0.002 (b)
Work related respiratory disability * 1 [0–1] 1 [0 – 2]. 0 [0 – 1]. 0.001 (b)
SGRQ total score * 43.7 [30.3-60.0] 46.2 [32.5-63.4] 42.0 [29.9-58.2] NS (b)
1: during the previous year (answers to SGRQ questions, symptoms domain).
*: analysis restricted to patients with available SGRQ: n = 424 (VDGF+: n = 144; VDGF-: n = 280). Answers were converted to continuous variables. Data are median
[Q1 – Q3] or %.
(a) = Chi-Square Test.
(b) =Wilcoxon rank-sum test.
p values are for differences between VGDF + and VGDF.
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could be hypothesized that, in predisposed subjects,
tobacco smoking may facilitate the development of atopy
through its effect on IgE levels [24]. In patients subse-
quently exposed to occupational sensitizing agents, this
may lead to the development of asthma-like features.
Association between occupational exposures, asthma-like
symptoms and lung function
Persistent wheeze, which was associated with VDGF ex-
posure in our series of COPD patients, can be a feature
of airway hyperresponsiveness (AHR) [25]. AHR is a car-
dinal feature of asthma [26] and may contribute to the
development of COPD [27]. Indeed, several studies
found an increase in the risk of COPD in patients report-
ing a personal history of asthma or AHR [8,28].
A longitudinal study of males with early COPD sug-
gested that occupational exposure to fumes could be
associated with an increased rate of decline of lung func-
tion [29]. However, in our population, lung function of
exposed patients did not differ from that of patients with
no reported occupational exposure. This discrepancy
could relate to the lower cumulative smoking in exposed
patients, or to an improvement in occupational condi-
tions with aging, related to seniority in the job [30].
Association between occupational exposures and
respiratory disability
In subjects with COPD, exposure to VDGF appears to
promote transient or even permanent work loss due torespiratory disability. Only a few studies reported work
loss associated with COPD. In the ECRHS, which
included adults aged 20 to 44 years, job change due to
breathing difficulties at work was reported by 4% of the
whole studied population. This figure increased to 11%
in subjects reporting either asthma or chronic bronchitis
[31]. In the confronting COPD international survey
(mean age 63.3 years), more than one third of persons
with COPD (35.7%) reported that their condition kept
them from working [32]. In a community based cohort
study using structured telephone interviews of 234
COPD patients, 25% reported respiratory disability at
work and 16% reported both VDGF exposures and re-
spiratory-related work disability [6]. In a patient series of
185 male patients, 34 had become unemployed (18%)
due to COPD [9]. Our patient series is in agreement with
these studies, with 28.5 % of patients reporting cessation
of work due to breathing, which is likely associated to
both social and economical consequences.
Accuracy of exposure assessment and other limitations
and strengths of the study
Assessment of occupational exposure was relatively
crude in this study, since self-reported exposure based
on a single item is subject to recall bias or subjective
influences, in contrast to job-exposure matrix (JEM),
which is considered as the “gold standard”. However,
previous studies performed in the general population
suggest that, when compared to complex assessments










Figure 1 Main differences between VDGF+and VDGF- COPD patients. All differences are significant at the p< 0.05 level except life time
asthma (p = 0.06) and FEV1(p = 0.08). Reported definitive and transient interruptions of work are those related to respiratory problems.
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and disease [33]. For instance, in two cohort studies of
adults with asthma, self-reported VDGF exposure was
fairly sensitive (71%) when compared to JEM-defined ex-
posure [34] and performed well against a checklist of 16
specific exposures [35]. In addition, several studies found
increased respiratory symptoms in association with self-
reported VDGF exposure [36,37]. For instance, one study
of subjects with established COPD showed that prior ex-
posure to VDGF was associated with increased symp-
toms over a 1 year follow-up [6]. Finally and
importantly, the job-exposure matrix analysis in our sub-
jects reporting VDGF exposure confirmed the reality of
exposure. In the present study, statistical analyses using
job-exposure matrix were performed to explore the rela-
tionship between the type of exposure and the presence
of atopy, hay fever, asthma and wheezing; however, due
to the relatively low number of patients in each individ-
ual category, it was not possible to draw any firm conclu-
sion (data not shown).
Since patients recruited in the real-life observational
Initiatives BPCO cohort are all followed in tertiary care
centers, they cannot be considered as representative of
the general COPD population. In addition, although cen-
ters were asked to include all consecutive COPD patients
visiting their clinic, it is likely that recruitment was not
exhaustive and varied with local resources affected to the
study, competitive studies (subjects could not be
included in the cohort if they participated to another
study) and the effective duration of each center’s partici-
pation to the cohort constitution. However, although we
cannot formally test the issue of selection bias, it mustbe noted that (i) the study protocol did not mention any
specific guidance on risk factors and (ii) the proportion
of patients with occupational exposures is similar to
what has been reported in other cohorts. Therefore, a se-
lection bias appears quite unlikely to influence the
results of the present analyses.
Pre-bronchodilator FEV1 was not available for all sub-
jects, which prevented us from including reversibility
data in the studied variables. Patients exposed to VDGF
could have more reversible airway obstruction, corre-
sponding to the asthma-like symptoms (increased fre-
quency of current wheeze) that were reported. However,
we have no way to test this hypothesis and, in general,
the relationship between symptoms and lung function
variables including reversibility is poor. Along the same
line, it would have been interesting to compare lung
volumes, diffusing capacity, and non-specific bronchial
hyperresponsiveness between exposed and unexposed
patients. However, these measurements were unavailable
in most subjects, as explained by the real-life nature of
the cohort. Similar concerns can be expressed for skin
prick tests.
A particular aspect of this patient series is that, to limit
the risk of including predominantly asthmatic subjects
with fixed airflow obstruction, it happened that all cen-
ters included only smokers or ex-smokers. This was both
a strength since it “secured” the diagnosis of COPD, and
a limitation in that it precluded analyzes of the role of
occupational exposures in never-smokers. However, it
did not prevent from identifying specific clinical features
in exposed patients. Similar studies in never-smoking
subjects with COPD would be of interest to determine
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or of VDGF-cigarette smoke interactions.
Another area of interest is the respective weight of risk
factors as determinants of the severity of airflow ob-
struction. Although presented analyses were not initially
designed to address this research question, we explored
this issue using two multivariate models: one was a lo-
gistic regression analysis with GOLD stage as dependent
variable, the other was a multilinear regression with
FEV1 (% predicted) as the dependent variable. Smoking
was accounted for using cumulative consumption in
pack-years and smoking status at inclusion (present vs
past smoking). Variables reflecting atopy were patient-
reported hay fever and familial history of atopy. With
the first model, only less than 2% (R2 = 0,018, p value of
the model: 0.46) of variations in the GOLD classification
could be explained by risk factors. In the second model,
R2 was even lower (0.0089, with a p value for the model
of 0.28). Thus, it can be concluded that, in this population
of smokers and ex-smokers, risk factors (age, smoking, oc-
cupational exposure, atopy) are very poorly correlated with
the severity of airflow obstruction, which makes it impos-
sible to draw any conclusion as to their respective weight.
Conclusions
This is the first study to demonstrate that occupational
exposures are associated with distinct clinical character-
istics in smokers and ex-smokers with COPD, i.e. (i)
older age and predominantly male gender, (ii) more fre-
quent respiratory-related work disability or handicap and
(iii) increased prevalence of hay fever, asthma, current
sputum production, lifetime and current wheezing. This
may help targeting subjects for preventive measures. Our
findings need to be confirmed and expanded in other
cohorts, which should also aim at identifying more pre-
cisely which occupational pollutants are involved and
which exposure thresholds (dose, duration, frequency)
are associated with an increased risk.
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